RecruitingNCT01915511

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Duke University
Principal Investigator: Scott Palmer, MD
Duke Clinical Research Institute, Duke University
Enrollment: 3000 enrolled
Eligibility: 21 years · All sexes
Timeline: 2014 – 2031

Study locations (30)

University of Alabama - Birmingham, Birmingham, Alabama, United States
University of Arizona, Tucson, Arizona, United States
University of California - Los Angeles, Los Angeles, California, United States
University of Southern California, Los Angeles, California, United States
Stanford University, Stanford, California, United States
Yale University, New Haven, Connecticut, United States
University of Florida, Gainesville, Florida, United States
University of South Florida, Tampa, Florida, United States
Emory University, Atlanta, Georgia, United States
Piedmont Healthcare, Austell, Georgia, United States
University of Chicago, Chicago, Illinois, United States
Northwestern University, Evanston, Illinois, United States
Loyola University Health System, Maywood, Illinois, United States
University of Kansas, Kansas City, Kansas, United States
Tulane University, New Orleans, Louisiana, United States
+15 more locations on ClinicalTrials.gov

Collaborators

Boehringer Ingelheim

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01915511 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials